Natera (NTRA) is higher today after a recent Delaware federal court decision set an ongoing royalty of 30% on certain post-injunction revenues from infringing MRD-related product sales by ArcherDx and Invitae that fall within exceptions to an existing injunction. The decision also left intact key findings on patent validity and infringement, keeping Natera’s enforcement win centered on MRD technology closely tied to its Signatera franchise. (investor.natera.com)

An “ongoing royalty” can be viewed as a continuing revenue claim on a competitor’s covered sales, which investors often value as a longer-duration cash-flow lever versus a one-time damages award. Today’s move suggests traders are recalibrating the potential financial impact of the 30% rate and the strength of Natera’s IP moat in MRD testing, where pricing power and reimbursement progress can hinge on perceived clinical and competitive differentiation. (investor.natera.com)

Key next steps for investors are the practical mechanics: what portion of sales qualify as post-injunction “exceptions,” when royalty payments begin flowing, and whether any additional post-trial motions or appeals change timing or scope. Any further commentary from the company on expected financial impact—or disclosures around enforcement and collections—could drive follow-through volatility in the shares. (investor.natera.com)